A Phase 2, Open-Label Study to Evaluate the Performance and Safety of ONM100, an Intraoperative Fluor Imaging Agent for the Detection of Peritoneal Mets
Latest Information Update: 11 Nov 2024
Price :
$35 *
At a glance
- Drugs Pegsitacianine (Primary)
- Indications Appendiceal cancer; Cancer metastases; Carcinoma; Colorectal cancer; Endometrial cancer; Mesothelioma; Ovarian cancer; Pancreatic cancer; Peritoneal cancer
- Focus Diagnostic use
- Sponsors OncoNano Medicine
- 01 Jul 2024 Results of this study presented in the Annals of Surgical Oncology
- 06 Jun 2023 Status changed to completed, according to results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2023 According to results presented at the 59th Annual Meeting of the American Society of Clinical Oncology, Pegsitacianine received Breakthrough Therapy Designation from the U.S. Food and Drug Administration as a result of data collected in this trial.